← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
490 Biotech, Inc.
Knoxville, TN
$4,789,357
Total funding
9
Grants
Funding over time
peak $1.1M · FY2013–20$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,789,357 · 9
By mechanism
R44$2,983,274 · 3
R42$993,957 · 1
R43$662,166 · 4
R41$149,960 · 1
Investigators at 490 Biotech, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicals$538,007
R44 · FY2015 · ES
Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows$522,620
R44 · FY2017 · GM
Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs$499,634
R44 · FY2019 · ES
Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine$497,759
R42 · FY2018 · GM
Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine$496,198
R42 · FY2017 · GM
Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs$491,375
R44 · FY2020 · ES
Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows$473,892
R44 · FY2018 · GM
Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicals$457,746
R44 · FY2016 · ES
Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs$224,924
R43 · FY2015 · ES
Autonomously-activating bioluminescent reporters to enable continuous, real-time, non-invasive brain cell imaging$150,000
R43 · FY2018 · MH
Expressing humanized bacterial luciferase in stem cells: Moving beyond firefly luciferase to expand the informational capacity of animal models for regenerative medicine$149,960
R41 · FY2015 · GM
Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows$149,051
R43 · FY2015 · GM
Expressing bacterial bioluminescence in human cell lines: Engineering autobiolumi$138,191
R43 · FY2013 · ES